Company intelligence / Profile preview

OptiNose

Yardley, Pennsylvania, United Statesoptinose.com ↗

Ownership: Public · OPTN
Employees: ~128
Development stage: Other

Overview

XHANCE® has demonstrated efficacy in Phase III trials for chronic rhinosinusitis with and without nasal polyps. The ReOpen1 trial met both co-primary endpoints, showing reduction in inflammation inside the sinus cavities. If replicated, this could make XHANCE the first intranasal drug approved specifically for chronic sinusitis. Other programs are earlier-stage or outlicensed.

Therapeutic areas: PsychiatryImmunologyNeurologyInfectious Diseases
Modalities: Small moleculeDevicePeptide
Industry: Biotech

Drug pipeline

2 assets

OPN-300

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Avanir Pharmaceuticals/Otsuka America Inc. – Onzetra Xsail outlicensing agreement

Financials

Market cap: $97.2M
Total revenue: $18.5M
Enterprise value: $152.7M

Beyond the preview

Go deeper on OptiNose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OptiNose.

Explore the full profile